- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Jasmine Kway PhD
Chief Executive Officer, Singapore Volition
Jasmine is the Chief Executive Officer of Singapore Volition having joined the company in 2017.
Jasmine is the Chief Executive Officer of Singapore Volition having joined the company in 2017. She has a proven track record of developing strategic business alliances and has established great connections across Asia for Volition. As a thought leader in technology management and commercialization, Jasmine has worked with numerous health and regulatory bodies across Asia and has successfully commercialized technologies and expanded companies into the Asian markets.
Jasmine received a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.
“The infectious energy and passion of the team is our key advantage. With strong science and belief, Volition’s vision to develop a low-cost effective platform to detect cancers will be a reality in the near future.”
Jasmine Kway
Chief Executive Officer, Singapore Volition